UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 356

Sortiert nach

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

The New England journal of medicine, 2014-01, Vol.370 (3), p.211-221

2014

Volltextzugriff (PDF)

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

The New England journal of medicine, 2012-01, Vol.366 (3), p.216-224

2012

Volltextzugriff (PDF)

Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1

The New England journal of medicine, 2014-01, Vol.370 (3), p.222-232

2014

Volltextzugriff (PDF)

Drug-drug interactions during antiviral therapy for chronic hepatitis C

Nature reviews. Gastroenterology & hepatology, 2013-10, Vol.10 (10), p.596

2013

Volltextzugriff (PDF)

Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions

World journal of gastroenterology : WJG, 2017-03, Vol.23 (9), p.1618-1626

2017

Volltextzugriff (PDF)

Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease

Gastroenterology (New York, N.Y. 1943), 2009-01, Vol.136 (1), p.138-148

2009

Volltextzugriff (PDF)

Within‐individual reproducibility of a dual sample oral cholate challenge test (DuO) and simplified versions of the HepQuant SHUNT test

Clinical and translational science, 2024-04, Vol.17 (4), p.e13786-n/a

2024

Volltextzugriff (PDF)

Adult-to-Adult Transplantation of the Right Hepatic Lobe from a Living Donor

The New England journal of medicine, 2002-04, Vol.346 (14), p.1074-1082

2002

Volltextzugriff (PDF)

PHOENIX: A randomized controlled trial of peginterferon alfa‐2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus

Liver transplantation, 2011-05, Vol.17 (5), p.528-538

2011

Volltextzugriff (PDF)

Somatostatin, Estrogen, and Polycystic Liver Disease

Gastroenterology (New York, N.Y. 1943), 2013-08, Vol.145 (2), p.279-282

2013

Volltextzugriff (PDF)

Management of the Transplant Recipient with Chronic Hepatitis C

Clinics in liver disease, 2013-02, Vol.17 (1), p.73-91

2013

Volltextzugriff (PDF)

Herbal product use by persons enrolled in the hepatitis C Antiviral Long‐Term Treatment Against Cirrhosis (HALT‐C) Trial

Hepatology (Baltimore, Md.), 2008-02, Vol.47 (2), p.605-612

2008

Volltextzugriff (PDF)

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT‐C trial

Hepatology (Baltimore, Md.), 2006-12, Vol.44 (6), p.1675-1684

2006

Volltextzugriff (PDF)

HCV NS5B Polymerase Inhibitors

Clinics in liver disease, 2009-08, Vol.13 (3), p.453-465

2009

Volltextzugriff (PDF)

Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients

Liver international, 2016-02, Vol.36 (2), p.189-197

2016

Volltextzugriff (PDF)

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

Gastroenterology (New York, N.Y. 1943), 2015-09, Vol.149 (3), p.649-659

2015

Volltextzugriff (PDF)

Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT‐C trial

Hepatology (Baltimore, Md.), 2009-12, Vol.50 (6), p.1738-1749

2009

Volltextzugriff (PDF)

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

The New England journal of medicine, 2009-04, Vol.360 (18), p.1827-1838

2009

Volltextzugriff (PDF)

Outcomes in hepatitis C virus–infected recipients of living donor vs. deceased donor liver transplantation

Liver transplantation, 2007-01, Vol.13 (1), p.122-129

2007

Volltextzugriff (PDF)

Waiting for “The Liver” – No Longer?

Journal of hepatology, 2016-09, Vol.65 (3), p.467-469

Everson, Gregory T

2016

Volltextzugriff (PDF)

Advances in noninvasive measurement of liver function and physiology: The HepQuant DuO test

Basic & clinical pharmacology & toxicology, 2024-03, Vol.134 (3), p.385-395

2024

Volltextzugriff (PDF)

Review and management of drug interactions with boceprevir and telaprevir

Hepatology (Baltimore, Md.), 2012-05, Vol.55 (5), p.1620-1628

2012

Volltextzugriff (PDF)

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

The New England journal of medicine, 2011-09, Vol.365 (11), p.1014-1024

2011

Volltextzugriff (PDF)

Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial

Gastroenterology (New York, N.Y. 1943), 2009-12, Vol.137 (6), p.1986-1994

2009

Volltextzugriff (PDF)

1 – 25 von 356

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(336)
Mit Volltextzugriff
(305)

Publikationsform

Artikel
(347)
Buchkapitel
(9)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(232)
Life Sciences & Biomedicine
(223)
Humans
(219)
Gastroenterology & Hepatology
(146)
Male
(145)
Female
(141)
Middle Aged
(120)
Adult
(107)
Biological And Medical Sciences
(85)
Medical Sciences
(79)
Hepatitis C, Chronic - Drug Therapy
(74)
Antiviral Agents - Therapeutic Use
(69)
Treatment Outcome
(56)
Aged
(55)
Transplantation
(52)
Drug Therapy, Combination
(51)
Liver Transplantation
(51)
Surgery
(50)
Hepacivirus - Genetics
(47)
Gastroenterology And Hepatology
(45)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1

Drug-drug interactions during antiviral therapy for chronic hepatitis C

Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions

Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease

Within‐individual reproducibility of a dual sample oral cholate challenge test (DuO) and simplified versions of the HepQuant SHUNT test

Adult-to-Adult Transplantation of the Right Hepatic Lobe from a Living Donor

PHOENIX: A randomized controlled trial of peginterferon alfa‐2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus

Somatostatin, Estrogen, and Polycystic Liver Disease

Management of the Transplant Recipient with Chronic Hepatitis C

Herbal product use by persons enrolled in the hepatitis C Antiviral Long‐Term Treatment Against Cirrhosis (HALT‐C) Trial

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT‐C trial

HCV NS5B Polymerase Inhibitors

Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT‐C trial

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

Outcomes in hepatitis C virus–infected recipients of living donor vs. deceased donor liver transplantation

Waiting for “The Liver” – No Longer?

Advances in noninvasive measurement of liver function and physiology: The HepQuant DuO test

Review and management of drug interactions with boceprevir and telaprevir

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial

Suchergebnisse filtern